The Experts below are selected from a list of 20538 Experts worldwide ranked by ideXlab platform
Elena Provenzano - One of the best experts on this subject based on the ideXlab platform.
-
use of ultrasound guided axillary Node Core biopsy in staging of early breast cancer
European Radiology, 2009Co-Authors: P D Britton, A Goud, S Godward, S Barter, A H Freeman, M Gaskarth, P Rajan, R Sinnatamby, J Slattery, Elena ProvenzanoAbstract:The aim of this study was to see how effective ultrasound-guided needle biopsy was at detecting lymph Node involvement in patients with early breast cancer. Patients with newly diagnosed invasive breast cancer underwent axillary ultrasound (US) where lymph Node size and morphology were noted. A Core biopsy (CB) was undertaken of any Node greater than 5 mm in longitudinal section. Patients with benign CBs proceeded to sentinel lymph Node (SLN) biopsy, whereas those with malignancy underwent axillary lymph Node dissection (ALND). US and CB findings were correlated with final surgical histology in all cases. One hundred and thirty-nine patients were examined, of whom 52.5% had lymph Node metastases on final histology. One hundred and twenty-one patients (87%) underwent axillary Node CB. The overall sensitivity of CB for detecting lymph Node metastases was 53.4% (60.3% for macrometastases; 26.7% for micrometastases). The US morphological characteristics most strongly associated with malignancy were absence of a hilum and a cortical thickness greater than 4 mm. However, one third of patients with normal lymph Node morphology had nodal metastases, and only 12% of these were diagnosed on CB. CB of axillary lymph Nodes can diagnose a substantial number of patients with lymph Node metastases, allowing these patients to proceed directly to ALND, avoiding unnecessary SLN biopsy.
-
ultrasound guided percutaneous axillary lymph Node Core biopsy how often is the sentinel lymph Node being biopsied
The Breast, 2009Co-Authors: P D Britton, A Goud, S Barter, M Gaskarth, R Sinnatamby, Elena Provenzano, P Moyle, Matthew G Wallis, John R Benson, Parto ForouhiAbstract:Patients with breast cancer now frequently undergo axillary ultrasound and Core biopsy (CB) in an attempt to reduce the number of unnecessary sentinel lymph Node (SLN) biopsies. This study aimed to establish the frequency of successful targeting of the SLN by ultrasound guided biopsy. A total of 137 patients had axillary ultrasound of which 121 underwent CB. 73 (60%) patients proceeded to SLN after negative CB. All SLNs were examined for evidence of metastases and previous CB. Of the 73 patients, 51 had no evidence of malignancy in the SLN (true negative=70%). However nodal deposits were found in the remaining 22 patients, representing a false negative rate for CB of 30%. Overall histopathological evidence of previous CB was identified in 47 (64%) of 73 patients undergoing SLN biopsy. The reason for false negative findings in the 22 (30%) patients was failure to sample the sentinel lymph Node in 10 (45%) and failure to sample the metastatic disease in the sentinel Node in 11 (55%). This study suggests that both better methods of identifying the sentinel lymph Node and more adequate sampling are required.
P D Britton - One of the best experts on this subject based on the ideXlab platform.
-
use of ultrasound guided axillary Node Core biopsy in staging of early breast cancer
European Radiology, 2009Co-Authors: P D Britton, A Goud, S Godward, S Barter, A H Freeman, M Gaskarth, P Rajan, R Sinnatamby, J Slattery, Elena ProvenzanoAbstract:The aim of this study was to see how effective ultrasound-guided needle biopsy was at detecting lymph Node involvement in patients with early breast cancer. Patients with newly diagnosed invasive breast cancer underwent axillary ultrasound (US) where lymph Node size and morphology were noted. A Core biopsy (CB) was undertaken of any Node greater than 5 mm in longitudinal section. Patients with benign CBs proceeded to sentinel lymph Node (SLN) biopsy, whereas those with malignancy underwent axillary lymph Node dissection (ALND). US and CB findings were correlated with final surgical histology in all cases. One hundred and thirty-nine patients were examined, of whom 52.5% had lymph Node metastases on final histology. One hundred and twenty-one patients (87%) underwent axillary Node CB. The overall sensitivity of CB for detecting lymph Node metastases was 53.4% (60.3% for macrometastases; 26.7% for micrometastases). The US morphological characteristics most strongly associated with malignancy were absence of a hilum and a cortical thickness greater than 4 mm. However, one third of patients with normal lymph Node morphology had nodal metastases, and only 12% of these were diagnosed on CB. CB of axillary lymph Nodes can diagnose a substantial number of patients with lymph Node metastases, allowing these patients to proceed directly to ALND, avoiding unnecessary SLN biopsy.
-
ultrasound guided percutaneous axillary lymph Node Core biopsy how often is the sentinel lymph Node being biopsied
The Breast, 2009Co-Authors: P D Britton, A Goud, S Barter, M Gaskarth, R Sinnatamby, Elena Provenzano, P Moyle, Matthew G Wallis, John R Benson, Parto ForouhiAbstract:Patients with breast cancer now frequently undergo axillary ultrasound and Core biopsy (CB) in an attempt to reduce the number of unnecessary sentinel lymph Node (SLN) biopsies. This study aimed to establish the frequency of successful targeting of the SLN by ultrasound guided biopsy. A total of 137 patients had axillary ultrasound of which 121 underwent CB. 73 (60%) patients proceeded to SLN after negative CB. All SLNs were examined for evidence of metastases and previous CB. Of the 73 patients, 51 had no evidence of malignancy in the SLN (true negative=70%). However nodal deposits were found in the remaining 22 patients, representing a false negative rate for CB of 30%. Overall histopathological evidence of previous CB was identified in 47 (64%) of 73 patients undergoing SLN biopsy. The reason for false negative findings in the 22 (30%) patients was failure to sample the sentinel lymph Node in 10 (45%) and failure to sample the metastatic disease in the sentinel Node in 11 (55%). This study suggests that both better methods of identifying the sentinel lymph Node and more adequate sampling are required.
Samia Mourah - One of the best experts on this subject based on the ideXlab platform.
-
image guided lymph Node Core needle biopsy predicts survival in mycosis fungoides and sezary syndrome
British Journal of Dermatology, 2021Co-Authors: Julien Calvani, A De Masson, C De Margeriemellon, E De Kerviler, C Ramwolff, A Gruber, Veronique Meignin, P Brice, Aurelie Sadoux, Samia MourahAbstract:BACKGROUND The prognosis of Sezary syndrome (SS) and mycosis fungoides (MF) depends on lymph Node (LN) involvement. The usefulness of LN image-guided Core-needle biopsies (CNBs), instead of surgical sampling, has been poorly evaluated. OBJECTIVES To determine the prognostic value of LN CNB in MF/SS. METHODS A retrospective search was conducted to identify all LN biopsy specimens of MF/SS between 2008 and 2019. Biopsies were staged according to the International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer (ISCL/EORTC) criteria. We performed immunolabelling and determined the tumour clone frequency (TCF) by high-throughput sequencing of the T-cell receptor beta locus. RESULTS We included 119 consecutive biopsies from 100 patients, 45 with MF and 55 with SS. N1, N2 and N3 stages were diagnosed in 34 (29%), 26 (22%) and 59 (49%) cases, respectively. The TCF, Ki67 index, and percentage of cells positive for thymocyte selection-associated high mobility group box protein (TOX), programmed cell death protein 1 (PD1), killer cell immunoglobulin-like receptor 3DL2 (KIR3DL2) and cluster of differentiation (CD)30 were all positively correlated with the N stage. Median overall survival (OS) for N1/N2 vs. N3 patients was 42 months (range 26-not reached) vs. 14 months (range 5-30), respectively (P 75 years, LN short-axis diameter > 15 mm, N3 stage, presence of large-cell transformation, TOX > 60%, PD1 > 25%, Ki67 > 30%, KIR3DL2 > 15%, CD30 > 10% and TCF > 25% were identified as adverse prognostic factors. In multivariate analyses, only an age > 75 years and Ki67 index > 30% were associated with reduced OS. We developed a new prognostic index associating the N stage and the Ki67 index, which better discriminates N3 patients with poor prognosis. CONCLUSIONS CNB allows an objective assessment of the LN involvement in MF/SS, relevant for staging and prognosis.
M Gaskarth - One of the best experts on this subject based on the ideXlab platform.
-
use of ultrasound guided axillary Node Core biopsy in staging of early breast cancer
European Radiology, 2009Co-Authors: P D Britton, A Goud, S Godward, S Barter, A H Freeman, M Gaskarth, P Rajan, R Sinnatamby, J Slattery, Elena ProvenzanoAbstract:The aim of this study was to see how effective ultrasound-guided needle biopsy was at detecting lymph Node involvement in patients with early breast cancer. Patients with newly diagnosed invasive breast cancer underwent axillary ultrasound (US) where lymph Node size and morphology were noted. A Core biopsy (CB) was undertaken of any Node greater than 5 mm in longitudinal section. Patients with benign CBs proceeded to sentinel lymph Node (SLN) biopsy, whereas those with malignancy underwent axillary lymph Node dissection (ALND). US and CB findings were correlated with final surgical histology in all cases. One hundred and thirty-nine patients were examined, of whom 52.5% had lymph Node metastases on final histology. One hundred and twenty-one patients (87%) underwent axillary Node CB. The overall sensitivity of CB for detecting lymph Node metastases was 53.4% (60.3% for macrometastases; 26.7% for micrometastases). The US morphological characteristics most strongly associated with malignancy were absence of a hilum and a cortical thickness greater than 4 mm. However, one third of patients with normal lymph Node morphology had nodal metastases, and only 12% of these were diagnosed on CB. CB of axillary lymph Nodes can diagnose a substantial number of patients with lymph Node metastases, allowing these patients to proceed directly to ALND, avoiding unnecessary SLN biopsy.
-
ultrasound guided percutaneous axillary lymph Node Core biopsy how often is the sentinel lymph Node being biopsied
The Breast, 2009Co-Authors: P D Britton, A Goud, S Barter, M Gaskarth, R Sinnatamby, Elena Provenzano, P Moyle, Matthew G Wallis, John R Benson, Parto ForouhiAbstract:Patients with breast cancer now frequently undergo axillary ultrasound and Core biopsy (CB) in an attempt to reduce the number of unnecessary sentinel lymph Node (SLN) biopsies. This study aimed to establish the frequency of successful targeting of the SLN by ultrasound guided biopsy. A total of 137 patients had axillary ultrasound of which 121 underwent CB. 73 (60%) patients proceeded to SLN after negative CB. All SLNs were examined for evidence of metastases and previous CB. Of the 73 patients, 51 had no evidence of malignancy in the SLN (true negative=70%). However nodal deposits were found in the remaining 22 patients, representing a false negative rate for CB of 30%. Overall histopathological evidence of previous CB was identified in 47 (64%) of 73 patients undergoing SLN biopsy. The reason for false negative findings in the 22 (30%) patients was failure to sample the sentinel lymph Node in 10 (45%) and failure to sample the metastatic disease in the sentinel Node in 11 (55%). This study suggests that both better methods of identifying the sentinel lymph Node and more adequate sampling are required.
S Barter - One of the best experts on this subject based on the ideXlab platform.
-
use of ultrasound guided axillary Node Core biopsy in staging of early breast cancer
European Radiology, 2009Co-Authors: P D Britton, A Goud, S Godward, S Barter, A H Freeman, M Gaskarth, P Rajan, R Sinnatamby, J Slattery, Elena ProvenzanoAbstract:The aim of this study was to see how effective ultrasound-guided needle biopsy was at detecting lymph Node involvement in patients with early breast cancer. Patients with newly diagnosed invasive breast cancer underwent axillary ultrasound (US) where lymph Node size and morphology were noted. A Core biopsy (CB) was undertaken of any Node greater than 5 mm in longitudinal section. Patients with benign CBs proceeded to sentinel lymph Node (SLN) biopsy, whereas those with malignancy underwent axillary lymph Node dissection (ALND). US and CB findings were correlated with final surgical histology in all cases. One hundred and thirty-nine patients were examined, of whom 52.5% had lymph Node metastases on final histology. One hundred and twenty-one patients (87%) underwent axillary Node CB. The overall sensitivity of CB for detecting lymph Node metastases was 53.4% (60.3% for macrometastases; 26.7% for micrometastases). The US morphological characteristics most strongly associated with malignancy were absence of a hilum and a cortical thickness greater than 4 mm. However, one third of patients with normal lymph Node morphology had nodal metastases, and only 12% of these were diagnosed on CB. CB of axillary lymph Nodes can diagnose a substantial number of patients with lymph Node metastases, allowing these patients to proceed directly to ALND, avoiding unnecessary SLN biopsy.
-
ultrasound guided percutaneous axillary lymph Node Core biopsy how often is the sentinel lymph Node being biopsied
The Breast, 2009Co-Authors: P D Britton, A Goud, S Barter, M Gaskarth, R Sinnatamby, Elena Provenzano, P Moyle, Matthew G Wallis, John R Benson, Parto ForouhiAbstract:Patients with breast cancer now frequently undergo axillary ultrasound and Core biopsy (CB) in an attempt to reduce the number of unnecessary sentinel lymph Node (SLN) biopsies. This study aimed to establish the frequency of successful targeting of the SLN by ultrasound guided biopsy. A total of 137 patients had axillary ultrasound of which 121 underwent CB. 73 (60%) patients proceeded to SLN after negative CB. All SLNs were examined for evidence of metastases and previous CB. Of the 73 patients, 51 had no evidence of malignancy in the SLN (true negative=70%). However nodal deposits were found in the remaining 22 patients, representing a false negative rate for CB of 30%. Overall histopathological evidence of previous CB was identified in 47 (64%) of 73 patients undergoing SLN biopsy. The reason for false negative findings in the 22 (30%) patients was failure to sample the sentinel lymph Node in 10 (45%) and failure to sample the metastatic disease in the sentinel Node in 11 (55%). This study suggests that both better methods of identifying the sentinel lymph Node and more adequate sampling are required.